For the second month straight, activity in the Biotechnology sector led the health care M&A market. In a slow month which saw a total of only 53 deals announced, the Biotech sector accounted for nine deals, or 17% of the total. Based on prices revealed to date,...
Our choice for Deal of the Month carries the largest price tag for February, and reflects a recent surge of interest in the Biotechnology sector. It is the largest deal this sector has seen since Amgen (NASDAQ: AMGN) acquired Immunex for $11.1 billion last year. After...
The fourth quarter capped 2002 with a surge of M&A activity not seen in four years. A total of 286 transactions were announced in 13 sectors of the health care industry. Although some of this volume may come from dealmakers’ desire to close deals and improve...
By several measures, it was a good year for health care M&A activity. At the date of this issue, a total of 895 transactions have been announced in the health care industry. With two weeks left in 2002, the year will surpass 900 deals. This figure represents a...
Our “Deal of the Month” goes to Laboratory Corporation of America’s (NYSE: LH) proposed acquisition of DIANON Systems (NASDAQ: DIAN) for just under $600 million. In its bid to become the premiere oncology laboratory company, LabCorp is making its richest...
With the stock market’s worst quarterly performance in 70 years, we might expect M&A activity to have taken a nose dive as well. And in fact, the overall market did suffer from a decreased deal count and smaller amounts of capital committed to deals. Even so, the...